Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-90301900 with chemoradiation followed by consolidation immunotherapy for unresectable stage III non-small cell lung cancer
ISRCTN81039232Phase 2Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Oct 2025
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised, open-label trial of NBTXR3 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Johnson & Johnson. Primary endpoint: Objective response rate. Started Oct 2025; status: recruiting.
02
Drugs
NBTXR3
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN81039232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81039232.